The White House and FDA are holding a series of meetings with cannabis industry stakeholders to discuss a new enforcement policy for CBD products.
The FDA has announced it will not pursue enforcement actions against certain hemp-derived oral CBD products, leading to a significant rally in cannabis stocks such as Tilray, Canopy Growth, and Curaleaf. This policy shift comes after the FDA missed its previous deadline to clarify regulations on cannabinoids. The meetings are part of a broader effort to establish clearer federal guidelines for the cannabis industry.
Investors and industry leaders are closely watching these developments, which could shape the future of CBD regulation in the U.S.
.Here are the top political news stories for today.
Join in on more popular conversations.